Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...